2MUS

HADDOCK calculated model of LIN5001 bound to the HET-s amyloid


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 200 
  • Conformers Submitted: 
  • Selection Criteria: target function 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Structure-based drug design identifies polythiophenes as antiprion compounds.

Herrmann, U.S.Schutz, A.K.Shirani, H.Huang, D.Saban, D.Nuvolone, M.Li, B.Ballmer, B.Aslund, A.K.Mason, J.J.Rushing, E.Budka, H.Nystrom, S.Hammarstrom, P.Bockmann, A.Caflisch, A.Meier, B.H.Nilsson, K.P.Hornemann, S.Aguzzi, A.

(2015) Sci Transl Med 7: 299ra123-299ra123

  • DOI: https://doi.org/10.1126/scitranslmed.aab1923
  • Primary Citation of Related Structures:  
    2MUS

  • PubMed Abstract: 

    Prions cause transmissible spongiform encephalopathies for which no treatment exists. Prions consist of PrP(Sc), a misfolded and aggregated form of the cellular prion protein (PrP(C)). We explore the antiprion properties of luminescent conjugated polythiophenes (LCPs) that bind and stabilize ordered protein aggregates. By administering a library of structurally diverse LCPs to the brains of prion-infected mice via osmotic minipumps, we found that antiprion activity required a minimum of five thiophene rings bearing regularly spaced carboxyl side groups. Solid-state nuclear magnetic resonance analyses and molecular dynamics simulations revealed that anionic side chains interacted with complementary, regularly spaced cationic amyloid residues of model prions. These findings allowed us to extract structural rules governing the interaction between LCPs and protein aggregates, which we then used to design a new set of LCPs with optimized binding. The new set of LCPs showed robust prophylactic and therapeutic potency in prion-infected mice, with the lead compound extending survival by >80% and showing activity against both mouse and hamster prions as well as efficacy upon intraperitoneal administration into mice. These results demonstrate the feasibility of targeted chemical design of compounds that may be useful for treating diseases of aberrant protein aggregation such as prion disease.


  • Organizational Affiliation

    Institute of Neuropathology, University Hospital of Zürich, University of Zürich, 8091 Zürich, Switzerland.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Heterokaryon incompatibility protein s
A, B, C, D, E
79Podospora anserinaMutation(s): 0 
Gene Names: het-ssmall s
UniProt
Find proteins for Q03689 (Podospora anserina)
Explore Q03689 
Go to UniProtKB:  Q03689
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ03689
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
3LS
Query on 3LS

Download Ideal Coordinates CCD File 
F [auth B]3''',4'-bis(carboxymethyl)-2,2':5',2'':5'',2''':5''',2''''-quinquethiophene-5,5''''-dicarboxylic acid
C26 H16 O8 S5
SZFMXSCJFCPHEZ-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 200 
  • Conformers Submitted: 
  • Selection Criteria: target function 

Structure Validation

View Full Validation Report



Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2017-02-01
    Type: Initial release
  • Version 1.1: 2017-02-22
    Changes: Database references
  • Version 1.2: 2018-06-13
    Changes: Data collection, Database references, Experimental preparation, Source and taxonomy, Structure summary